United Services Automobile Association Acquires New Holdings in Endocyte, Inc. (ECYT)

United Services Automobile Association acquired a new stake in Endocyte, Inc. (NASDAQ:ECYT) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 13,134 shares of the biopharmaceutical company’s stock, valued at approximately $181,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in ECYT. Birchview Capital LP acquired a new position in Endocyte in the second quarter valued at approximately $138,000. Guggenheim Capital LLC acquired a new position in Endocyte in the first quarter valued at approximately $145,000. Sigma Planning Corp acquired a new position in Endocyte in the second quarter valued at approximately $147,000. Legal & General Group Plc acquired a new position in Endocyte in the second quarter valued at approximately $149,000. Finally, BlueMountain Capital Management LLC acquired a new position in Endocyte in the second quarter valued at approximately $153,000. Institutional investors and hedge funds own 75.30% of the company’s stock.

ECYT opened at $23.47 on Tuesday. Endocyte, Inc. has a twelve month low of $2.81 and a twelve month high of $23.73.

Endocyte (NASDAQ:ECYT) last posted its earnings results on Tuesday, July 31st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.17). The company had revenue of $0.01 million for the quarter. Endocyte had a negative net margin of 69,330.66% and a negative return on equity of 30.87%. Research analysts forecast that Endocyte, Inc. will post -0.65 EPS for the current year.

Several equities analysts recently weighed in on ECYT shares. Zacks Investment Research upgraded shares of Endocyte from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Tuesday, July 10th. Wedbush increased their price objective on shares of Endocyte from $15.00 to $21.00 and gave the company an “outperform” rating in a report on Monday, July 16th. BidaskClub lowered shares of Endocyte from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 26th. Jefferies Financial Group restated a “buy” rating and issued a $21.00 price objective on shares of Endocyte in a report on Thursday, August 2nd. Finally, Cowen restated a “buy” rating on shares of Endocyte in a report on Monday, September 10th. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $20.00.

In other Endocyte news, CFO Michael T. Andriole sold 17,283 shares of the stock in a transaction on Friday, October 5th. The shares were sold at an average price of $15.55, for a total value of $268,750.65. Following the sale, the chief financial officer now directly owns 132,717 shares in the company, valued at $2,063,749.35. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Michael A. Sherman sold 28,146 shares of the stock in a transaction on Friday, October 5th. The stock was sold at an average price of $15.55, for a total transaction of $437,670.30. Following the completion of the sale, the chief executive officer now owns 347,918 shares in the company, valued at $5,410,124.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 68,354 shares of company stock worth $1,099,637. Company insiders own 10.65% of the company’s stock.

Endocyte Company Profile

Endocyte, Inc, a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

Recommended Story: Put Option

Institutional Ownership by Quarter for Endocyte (NASDAQ:ECYT)

Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply